- Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr ...🔍
- Prelude Therapeutics Inc. 🔍
- Prelude Therapeutics Announces Pricing of Initial Public Offering🔍
- Prelude Therapeutics prices IPO at $19🔍
- Prelude Therapeutics Announces Closing of Initial Public Offering ...🔍
- Cancer biotech Prelude Therapeutics prices IPO at $19🔍
- Prelude Therapeutics closes $158M IPO as share value surges🔍
- News Archive🔍
Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr ...
Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr ...
(RTTNews) - Prelude Therapeutics Inc (PRLD) announced that it has priced initial public offering of 8.325 million shares at $19 per share, the hig...
Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr ...
Prelude Therapeutics Inc (PRLD) announced that it has priced initial public offering of 8.325 million shares at $19 per share, ...
Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr ...
Prelude Therapeutics Inc (PRLD) announced that it has priced initial public offering of 8.325 million shares at $19 per share, the high end of expected ...
Prelude Therapeutics Inc. (PRLD) Prices 8.325M Share IPO at $19/Sh
The gross proceeds to Prelude, before deducting underwriting commissions and offering expenses, are expected to be approximately $158.2 million.
Prelude Therapeutics Announces Pricing of Initial Public Offering
The shares are expected to begin trading on the Nasdaq Global Select Market on September 25, 2020 under the ticker symbol “PRLD.” The offering ...
Prelude Therapeutics prices IPO at $19, higher end of expected ...
Biotech startup Prelude Therapeutics (PRLD) has priced its initial public offering of 8.325M shares at $19/share, for expected gross ...
Prelude Therapeutics Announces Closing of Initial Public Offering ...
WILMINGTON, Del., Sept. ... The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before ...
Cancer biotech Prelude Therapeutics prices IPO at $19, the high ...
Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 ...
Prelude Therapeutics closes $158M IPO as share value surges - DBT
Prelude Therapeutics closed its IPO Sept. 24 at its highest targeted price point of $19 a share, resulting in $158.2 million in proceeds.
News Archive | Markets Insider
Prelude Therapeutics Prices IPO Of 8.325 Mln Shares At $19/Shr, The High End Of Expected Range. 12:53 AM 09/25/2020 12:53:00 AM UTC-0400. Pangyo Techno ...
Prelude Therapeutics Launches Successful IPO - Choose Delaware
Prelude initially filed with the SEC to raise up to $100 million in an initial public offering, then increased the amount to $150 million. On ...
Latest IPO News (beta) - IPO Monitor
BRIEF-Tricida Announces Initial Public Offering 11.7 Mln Common Shares Priced At $19 Per Share · BJ's Wholesale Club IPO priced at $17 per share - source.